Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Novel lung cancer vaccine CV-9202 evaluated in phase I trial

Aug. 23, 2013

Generation of a human anticancer immune response using a dendritic cell-based vaccine

Aug. 22, 2013

MacroGenics doses first patient in phase I MGA-271 trial

Aug. 21, 2013

Patient enrolled in brain tumor vaccine trial at Northwestern Memorial Hospital

Aug. 19, 2013

Amorfix Life Sciences provides update on ovarian cancer program

Aug. 19, 2013

ADXS-HPV receives orphan drug designation for HPV-associated anal cancer

Aug. 19, 2013

Phase II trial of Adcetris in combination with standard of care for frontline DLBCL commences

Aug. 19, 2013

Altor receives IND clearance to advance ALT-803 into clinical trials in melanoma

Aug. 16, 2013

Patrys discloses additional data from phase I/II trial of PAT-SM6 in MM

Aug. 16, 2013

Immunomedics advances solid tumor ADC programs to phase II

Aug. 13, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...